Consistent with the deep and durable RAS signaling modulation, daily RMC-6236 treatment resulted in dose-dependent antitumor activity in a series of human tumor xenograft models harboring prevalent KRAS mutations, i.e., KRASG12D, KRASG12V, and KRASG12C. The gene discussed is KRAS; the disease is neoplasm.